Compare CRGO & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | BTMD |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 65.8M |
| IPO Year | 2022 | 2021 |
| Metric | CRGO | BTMD |
|---|---|---|
| Price | $1.34 | $1.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.40 | ★ $2.83 |
| AVG Volume (30 Days) | 37.9K | ★ 212.2K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,219,000.00 |
| Revenue This Year | $10.61 | $2.03 |
| Revenue Next Year | $16.85 | $6.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $1.27 |
| 52 Week High | $4.24 | $3.61 |
| Indicator | CRGO | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 31.74 |
| Support Level | $1.17 | $1.35 |
| Resistance Level | $1.43 | $1.69 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 78.85 | 8.33 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.